MAPT and Alzheimer disease: This approach comes from the efforts of Jack and colleagues, who developed a biomarker-based scheme named ATN to identify AD by detecting Aβ (A = amyloid), phosphorylated Tau (T = phosphorylated Tau), and neurodegeneration (N, defined as measurable total Tau) [13].